Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4

No abstract is available for this paper.

• Publication year

  2011

• Venue

  mAbs

• Publication date

  2011-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/mabs.3.4.15786PMID 21540647PMCID PMC3218534
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models

  2012cited by this paper
• CDR Repair: A Novel Approach to Antibody Humanization

  2010cited by this paper
• Current trends in monoclonal antibody development and manufacturing

  2010cited by this paper
• Validation of tissue cross reactivity (TCR) studies: Tissue cross reactivity of anti-human CD209 in cynomolgus tissues

  2009cited by this paper
• Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling.

  2009cited by this paper
• Rapid characterization of binding specificity and cross-reactivity of antibodies using recombinant human protein arrays.

  2009cited by this paper
• Preclinical safety evaluation of monoclonal antibodies.

  2008cited by this paper
• Role of antibody paratope conformational flexibility in the manifestation of molecular mimicry.

  2008cited by this paper
• Exploring the energy landscape of antibody-antigen complexes: protein dynamics, flexibility, and molecular recognition.

  2008cited by this paper
• Off-target activity of TNF-α inhibitors characterized by protein biochips

  2008cited by this paper
• Determination and validation of off-target activities of anti-CD44 variant 6 antibodies using protein biochips and tissue microarrays.

  2008cited by this paper
• Molecular evolution of affinity and flexibility in the immune system

  2007cited by this paper
• Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

  2007cited by this paper
• Molecular basis for the binding polyspecificity of an anti‐cholera toxin peptide 3 monoclonal antibody

  2006cited by this paper
• Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

  2006cited by this paper
• The Central Role of the Alternative Complement Pathway in Human Disease1

  2006cited by this paper
• Complement amplification revisited.

  2006cited by this paper
• Complement in BuB/BnJ mice revisited: serum C3 levels and complement opsonic activity are not elevated.

  2006cited by this paper
• Antibody engineering for the development of therapeutic antibodies.

  2005cited by this paper
• Polyreactivity of antibody molecules.

  2004cited by this paper
• High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold.

  2004cited by this paper
• Structural plasticity and the evolution of antibody affinity and specificity.

  2003cited by this paper
• The specificity of cross‐reactivity: Promiscuous antibody binding involves specific hydrogen bonds rather than nonspecific hydrophobic stickiness

  2003cited by this paper
• Antibody Multispecificity Mediated by Conformational Diversity

  2003cited by this paper
• Test of a statistical model for molecular recognition in biological repertoires.

  2002cited by this paper
• Continual Low-Level Activation of the Classical Complement Pathway

  2001cited by this paper
• Structure and biology of complement protein C3, a connecting link between innate and acquired immunity

  2001cited by this paper
• Serine 132 is the C3 covalent attachment point on the CH1 domain of human IgG1.

  2001cited by this paper
• Tissue microarray technology for high-throughput molecular profiling of cancer.

  2001cited by this paper
• UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions.

  2000cited by this paper
• Protein microchips: use for immunoassay and enzymatic reactions.

  2000cited by this paper
• Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA.

  1999cited by this paper
• Molecular basis for the binding promiscuity of an anti-p24 (HIV-1) monoclonal antibody.

  1997cited by this paper
• Antibody-antigen interactions: contact analysis and binding site topography.

  1996cited by this paper
• Covalent attachment of human complement C3 to IgG. Identification of the amino acid residue involved in ester linkage formation.

  1994cited by this paper
• Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries.

  1994cited by this paper
• IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts.

  1991cited by this paper
• Light-directed, spatially addressable parallel chemical synthesis.

  1991cited by this paper

• Targeting Colorectal Cancer Stem Cells Through Inhibition of the Fibroblast Growth Factor Receptor 4 Pathway with a Novel Antibody

  2026cites this paper
• Nonspecific Cellular Interactions Are a Key Determinant in the Disposition of Fc-Fused Proteins.

  2026cites this paper
• Prediction of Antibody Non-Specificity using Protein Language Models and Biophysical Parameters

  2026cites this paper
• FGF19 in Solid Tumors: Molecular Mechanisms, Metabolic Reprogramming, and Emerging Therapeutic Opportunities

  2026cites this paper
• Applications of Cell-Based Protein Array Technology to Preclinical Safety Assessment of Biological Products

  2025cites this paper
• AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies

  2025cites this paper
• Directed evolution of drug-like Aβ conformation-specific antibodies

  2025cites this paper
• Targeting Inflammatory Cytokines in Autoimmune Diseases: Mechanisms and Therapeutic Advances with Antibody-Based Therapies

  2025cites this paper
• A multiscale physiologically based pharmacokinetic model to support mRNA-encoded BiTE therapy in cancer treatment

  2025cites this paper
• In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies

  2024cites this paper
• In vivo affinity maturation of the CD4 domains of an HIV-1-entry inhibitor

  2024cites this paper
• The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics

  2024cites this paper
• Predicting monoclonal antibody binding sequences from a sparse sampling of all possible sequences

  2024cites this paper
• Therapeutic Applications of Aptamers

  2024cites this paper
• Tools to investigate the cell surface: Proximity as a central concept in glycoRNA biology.

  2024cites this paper
• In vivo affinity maturation of the HIV-1 Env-binding domain of CD4

  2024cites this paper
• In vivo affinity maturation of the HIV-1 Env-binding domain of CD4

  2024cites this paper
• In vivo affinity maturation of murine B cells reprogrammed to express human antibodies

  2023cites this paper
• Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice

  2023cites this paper
• Physicochemical Stimulus-Responsive Systems Targeted with Antibody Derivatives.

  2023cites this paper
• Bubble-Based Drug Delivery Systems: Next-Generation Diagnosis to Therapy

  2023cites this paper
• Overcoming the On‐Target Toxicity in Antibody‐Mediated Therapies via an Indirect Active Targeting Strategy

  2023cites this paper
• Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies

  2023cites this paper
• Biotherapeutics ADME and PK/PD Principles

  2022cites this paper
• A rational approach to assess off-target reactivity of a dual-signal integrator for T cell therapy.

  2022cites this paper
• Antibodies with Weakly Basic Isoelectric Points Minimize Trade-offs between Formulation and Physiological Colloidal Properties.

  2022cites this paper
• Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper

  2022cites this paper
• Non-specificity as the sticky problem in therapeutic antibody development

  2022cites this paper
• Understanding and Modulating Antibody Fine Specificity: Lessons from Combinatorial Biology

  2022cites this paper
• A unified peptide array platform for antibody epitope binning, mapping, specificity and predictive off-target binding

  2022cites this paper
• Automatic Web News Content Extraction

  2022cites this paper
• Therapeutic antibody development—Remington chapter

  2021cites this paper
• Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns

  2021cites this paper
• Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies

  2021cites this paper
• Stepping forward in antibody-drug conjugate development.

  2021cites this paper
• Opening doors with ultrasound and microbubbles: beating biological barriers to promote drug delivery.

  2021cites this paper
• The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation.

  2020cites this paper
• Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients

  2019cites this paper
• Structure, heterogeneity and developability assessment of therapeutic antibodies

  2019cites this paper
• An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans

  2019cites this paper
• New Advances in Cell Microarray Technology to Expand Applications in Target Deconvolution and Off-Target Screening

  2019cites this paper
• Monoclonal Antibodies: From Structure to Therapeutic Application

  2019cites this paper
• Survey Based Study to Assess the Principles, Assumptions, and Processes in Establishing Biologics Assets as a Fast to FIH (First-In-Human)

  2018cites this paper
• Inhibition of the signaling pathway of syndecan-1 by synstatin: A promising anti-integrin inhibitor of angiogenesis and proliferation in HCC in rats.

  2018cites this paper
• Single cell protein analysis for systems biology.

  2018cites this paper
• Anti-PD1 ‘SHR-1210ʹ aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement

  2018cites this paper
• Abuse liability assessment for biologic drugs – All molecules are not created equal

  2018cites this paper
• Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non‐Ig scaffolds

  2018cites this paper
• Principles, Assumptions, and Processes Established to Designate Biologics Assets as a Fast to FIH (First-in-Human) Program and the Associated Core Concepts for the Utilization of low and High-Risk Activities, Timelines and Functional Level Expectations

  2018cites this paper
• Practical considerations for chimeric antigen receptor design and delivery

  2017cites this paper
• Monoklonaler antikörper anti-fgfr4

  2017cites this paper
• FGFR a promising druggable target in cancer: Molecular biology and new drugs.

  2017cites this paper
• Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates

  2017cites this paper
• Tuning the specificity of a Two-in-One Fab against three angiogenic antigens by fully utilizing the information of deep mutational scanning

  2017cites this paper
• Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins

  2017cites this paper
• Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics

  2017cites this paper
• Critical Aspects of Integrated Nonclinical Drug Development

  2017cites this paper
• Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy

  2017cites this paper
• Roles of FGFR in oral carcinogenesis

  2016cites this paper
• Considerations and rationale for the selection of LC-MS/MS or ligand binding assays for bioanalysis of therapeutic proteins

  2016cites this paper
• Therapeutic uses of FGFs.

  2016cites this paper
• Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy.

  2016cites this paper
• Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies.

  2016cites this paper
• Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo

  2016cites this paper
• Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.

  2016cites this paper
• Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma

  2016cites this paper
• (125)I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma.

  2016cites this paper
• Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics*

  2015cites this paper
• Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies

  2015cites this paper
• Molecular Pathology Techniques in the Preclinical Development of Therapeutic Biologics

  2015cites this paper
• Pharmacokinetic properties of the preparations of protein origin

  2015cites this paper
• FGFR4 Is a Potential Predictive Biomarker in Oral and Oropharyngeal Squamous Cell Carcinoma

  2015cites this paper
• Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms

  2015cites this paper
• ADME for Therapeutic Biologics: What Can We Leverage from Great Wealth of ADME Knowledge and Research for Small Molecules

  2015cites this paper
• Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics

  2015cites this paper
• Therapeutic Antibodies—Protein Engineering to Influence ADME, PK, and Efficacy

  2015cites this paper
• An Anti-H5N1 Influenza Virus FcDART Antibody Is a Highly Efficacious Therapeutic Agent and Prophylactic against H5N1 Influenza Virus Infection

  2015cites this paper
• Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics

  2015cites this paper
• Chemopreventive and hepatoprotective effects of Epigallocatechin‐gallate against hepatocellular carcinoma: role of heparan sulfate proteoglycans pathway

  2014cites this paper
• Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge

  2014cites this paper
• Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.

  2014cites this paper
• Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

  2014cites this paper
• Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor

  2014cites this paper
• Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody

  2014cites this paper
• A High-Affinity Native Human Antibody Neutralizes Human Cytomegalovirus Infection of Diverse Cell Types

  2014cites this paper
• Early De-risking Strategy for Novel Biotherapeutics

  2013cites this paper
• Current challenges and opportunities in nonclinical safety testing of biologics.

  2013cites this paper
• Anticorps spécifiques contre le fgfr4 et méthodes d'utilisation

  2013cites this paper
• Biological Therapies for Cancer

  2013cites this paper
• Monoclonal Antibodies: From Structure to Therapeutic Application

  2013cites this paper
• Procédé de sélection d'agents thérapeutiques

  2013cites this paper
• Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration

  2012cites this paper
• Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

  2012cites this paper
• Multiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes

  2012cites this paper
• Molecular Pathways Molecular Pathways : Fibroblast Growth Factor Signaling : A New Therapeutic Opportunity in Cancer

  2012cites this paper
• Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to Humans

  2012cites this paper
• ADME of Biologics—What Have We Learned from Small Molecules?

  2012cites this paper
• Investigative safety science as a competitive advantage for Pharma

  2012cites this paper
• Maximizing tumour exposure to anti‐neuropilin‐1 antibody requires saturation of non‐tumour tissue antigenic sinks in mice

  2012cites this paper
• Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?

  2012cites this paper